Targeting Resistance: Liquid Biopsy and the Role of SERDs In ESR1-Mutated mBC

EP: 1.When Stable Disease Progresses: ESR1 Mutations at the Point Of Progression In Juliana’s Case

Now Viewing

EP: 2.Targeting Resistance: Liquid Biopsy and the Role of SERDs In ESR1-Mutated mBC

Video content above is prompted by the following:

The Oncology Nursing News program focuses on treatment strategies for ESR1-mutant hormone receptor-positive, HER2-negative breast cancer. Led by Tiffany A. Traina, MD, FASCO, from Memorial Sloan Kettering Cancer Center, the panel includes experienced health care professionals Melissa Rikal, MSN, FNP-BC, AOCNP, from Sarah Cannon Research Institute and Marissa Marti-Smith, DNP, APRN, AGNP-C, AOCNP, from Texas Oncology. The discussion aims to provide practical insights for optimal patient outcomes in metastatic breast cancer treatment.

The panelists bring diverse expertise in breast cancer care, with Rikal highlighting her 11-year experience in breast cancer clinical trials and Marti-Smith sharing her 13-year background in oncology nursing. Their combined experience spans various roles, including registered nursing, infusion care, and nurse practitioner positions specializing in breast oncology. This multidisciplinary approach ensures a comprehensive view of patient care and treatment strategies.

The program sets out to explore the nuanced approaches to treating patients with ESR1 mutations, focusing on emerging treatment options and clinical considerations. By combining clinical trial insights with real-world experience, the panelists aim to provide health care professionals with actionable knowledge about managing metastatic breast cancer, particularly in patients with specific genetic mutations and treatment histories.